Pavlos Msaouel, MD, PhD
Advertisement
Articles by Pavlos Msaouel, MD, PhD
Pavlos Msaouel, MD, PhD, discusses how exercise can influence risk for patients with sickle cell trait to develop renal medullary carcinoma.
Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.
Advertisement
Latest Updated Articles
Dr Msaouel on Ongoing Research With Bispecific Antibodies in RMC and Epithelioid SarcomaPublished: July 31st 2024 | Updated:
Dr. Msaouel on Rationale for Sitravatinib/Nivolumab Combo in Urothelial CancerPublished: December 13th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5